Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Imjudo (Tremelimumab-actl) 300 Mg/15 Ml Sdv (CDM 63600793) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 16, 2026 , from http://ppman.hank.ai/transparency/procedure/63600793/by-state?code_type=CDM
“Imjudo (Tremelimumab-actl) 300 Mg/15 Ml Sdv (CDM 63600793) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/63600793/by-state?code_type=CDM. Accessed
November 16, 2026 .
“Imjudo (Tremelimumab-actl) 300 Mg/15 Ml Sdv (CDM 63600793) by State,” HANK Price Transparency ,
accessed November 16, 2026 ,
http://ppman.hank.ai/transparency/procedure/63600793/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
63600793 — Imjudo (tremelimumab-actl) 300 Mg/15 Ml Sdv
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$99,080
National median
$81,952 – $124,976
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 63600793 (CDM), with interquartile range
State Median p25 p75
NC $99,080 $81,952 $124,976